Piper Jaffray’s healthcare analyst Joshua Schimmer is out today with research notes on biotech giants Biogen Inc (NASDAQ:BIIB) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), as shares of …
After a mostly red week, stocks gapped higher Friday morning with the latest jobs report. The jobless rate fell to 5.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is buying fellow ultra orphan drug developer Synageva Biopharma Corp (NASDAQ:GEVA) for $8.
Synageva Biopharma Corp (NASDAQ:GEVA) increased more than 130% to $221.25 in pre-market trading following news that the pharmaceutical company will be acquired by …
Over the past four years, the S&P 500 has increased a total of 66%. However, the Biotech sector outperformed the S&P 500 by …
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is a biopharmaceutical company that focuses on creating treatments for rare diseases.
In a research report issued today, William Blair analyst John Sonnier assigned an Outperform rating on Alexion (NASDAQ:ALXN). No price target was provided.
In a research note published today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on Alexion Pharmaceuticals (ALXN) with a $162 price …
